Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs

Journal of Nuclear Medicine

Volumn 47, Issue 12, 2006, Pages 1904-1907

  Mariani, Giuliano ^a   Erba, Paola A ^a   Signore, Alberto ^b,c  

^a UNIVERSITY OF PISA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; AMINOCAPROIC ACID; BOMBESIN; BOMBESIN TC 99M; CD 105; CHEMOKINE RECEPTOR CXCR4; ENDOGLIN; EXENDIN 4 IN 111; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEPTADECAPEPTIDE GASTRIN IODINE; LYSINE AMINOHEXANOIC ACID DIETHYLENETRIAMINEPENTAACETIC AMIDE IN 111; NEUROTENSIN DERIVATIVE IN 111; NEUROTENSIN[8-13] TC 99M; PENTETATE INDIUM IN 111; PENTETIC ACID; PEPTIDE; RADIOPHARMACEUTICAL AGENT; RP 593; RP 593 TC 99M; SOMATOSTATIN DERIVATIVE; TECHNETIUM 99M; TP 3654; TRACER; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165; VASOACTIVE INTESTINAL PEPTIDE I 123; DIAGNOSTIC AGENT; RADIOISOTOPE; RECEPTOR; SOMATOSTATIN;

BRAIN TUMOR; BREAST CANCER; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; GENE TARGETING; HUMAN; ISOTOPE LABELING; LUNG CANCER; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TUMOR; ANIMAL; DRUG DELIVERY SYSTEM; METABOLISM; METHODOLOGY; NEOPLASM; NOTE; SCINTISCANNING;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; ISOTOPE LABELING; NEOPLASMS; PEPTIDES; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; SOMATOSTATIN;

EID: 34547831141     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. 2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47:2025-2033.
2. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci. 1995;57:1249-1265.
3. Reubi JC, Schaer JC, Laissue JA, Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism. 1996;45:39-41.
4. Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. Digestion. 1994;55(suppl 3):54-59.
5. Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors: an overview of European results. Ann N Y Acad Sci. 1994;733:416-424.
6. Kwekkeboom DJ, Krenning EP. Somatostatin receptor scintigraphy in patients with carcinoid tumors. World J Surg. 1996;20:157-161.
7. 111Inoctreotide. Nucl Med Commun. 1995;16:756-766.
8. Fletcher WS, Lum SS, Nance RW, Pommier RF, O'Dorisio MS. The current status of somatostatin receptors in malignant melanoma. Yale J Biol Med. 1997;70:561-563.
9. 111In-DTPA-D-Phe-1- octreotide scintigraphy of small cell lung cancer. Q J Nucl Med. 1995;39(suppl 1):104-107.
10. van Eijck CH, Kwekkeboom DJ, Krenning EP. Somatostatin receptors and breast cancer. Q J Nucl Med. 1998;42:18-25.
11. Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: state of the science. J Nucl Med. 2003;44:1945-1961.
12. 111In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University experience, 1993to 1998. J Clin Oncol. 2000;18:1331-1336.
13. 99mTc-Labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med. 2000;41:107-110.
14. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med. 2000;27:1312-1317.
15. 111Inlabeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med. 1999;40:2081-2087.
16. Behr TM, Jenner N, Béhé M, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med. 1999;40:1029-1044.
17. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/ gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998;25:424-430.
18. Reubi JC, Waser B, Schaer JC, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med. 1998;25:481-490.
19. Behr TM, Jenner N, Béhé M, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med. 1999;40:1029-1044.
20. Behr TM, Béhé M. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97-107.
21. 99mTc-Labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine- based bifunctional chelating agent. Bioconjug Chem. 1999;10:254-260.
22. 99mTc- Bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging. 2003;30:1378-1382.
23. Baidoo KE, Lin KS, Zhan Y, Finley P, Sheffel U, Wagner HN Jr. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem. 1998;9:218-225.
24. Lin KS, Luu A, Baidoo KE, et al. A new high affinity technetium-99m- bombesin analogue with low abdominal accumulation. Bioconjug Chem. 2005;16:43-50.
25. 64Cu-labeled bombesin analogue. Bioconjug Chem. 2003;14:756-763.
26. 18F-Labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492-501.
27. Reubi JC, Waser B, Friess B, Buechler M, Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut. 1998;42:546-550.
28. 99mTc. J Nucl Med. 2002;43:374-383.
29. de Visser M, Janssen PJJM, Srinivasan A, et al. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med. 2003;30:1134-1139.
30. Li S, Peck-Radosavljevic M, Koller E, et al. Characterization of I-123 vascular endothelial growth factor-binding sites expressed on human tumor cells: possible implication for tumor imaging. Int J Cancer. 2001;91:789-796.
31. Li S, Peck-Radosavljevic M, Kienast O, et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol. 2003;14:1274-1277.
32. Liu S, Edwards DS, Ziegler MC, Harris AR, Hemingway SJ, Barrett JA. Tc-99m-labeling of a hydrozinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug Chem. 2001;12:624-629.
33. van Hagen PM, Breeman WAP, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer. 2000;90:186-198.
34. Haubner R, Wester H-J, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-336.
35. Haubner R, Wester HJ, Weber WA, et al. Non-invasive imaging of alphavbeta3 integrin expression using F-18-labelled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
36. Posey JA, Khazaeli MB, DelGrosso A, et al. A pilot trial of vitaxin, a humanized anti-vitronectin receptor (anti alphavbeta3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm. 2001;16:125-132.
37. Signore A, Capriotti G, Scopinaro F, Bonanno E, Modesti A. Radiolabelled lymphokines and growth factors for in vivo imaging of inflammation, infection and cancer. Trends Immunol. 2003;24:395-402.
38. Signore A, Chianelli M, Bei R, Oyen W, Modesti A. Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine [erratum]. Eur J Nucl Med Mol Imaging. 2003;30:801-802.